Erratum: Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis

被引：0
|
作者：
P Kapoor
S V Rajkumar
A Dispenzieri
M A Gertz
M Q Lacy
D Dingli
J R Mikhael
V Roy
R A Kyle
P R Greipp
S Kumar
S J Mandrekar
机构：
来源：
Leukemia | 2011年 / 25卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Correction to: Leukemia (2011) 4, 689–696; doi:10.1038/leu.2010.313; published online 14 January 2011 Since the publication of the above paper, the authors have noticed an error in Table 1. The number of MP and MPT patients in ‘IFM 01-01’ are 116 and 113, respectively; thus, the total number of patients listed should be 229 and not 226.
引用
收藏
页码：1523 / 1524
页数：1
相关论文
共 50 条
  • [1] Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
    Kapoor, P.
    Rajkumar, S. V.
    Dispenzieri, A.
    Gertz, M. A.
    Lacy, M. Q.
    Dingli, D.
    Mikhael, J. R.
    Roy, V.
    Kyle, R. A.
    Greipp, P. R.
    Kumar, S.
    Mandrekar, S. J.
    LEUKEMIA, 2011, 25 (04) : 689 - 696
  • [2] Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis
    P Kapoor
    S V Rajkumar
    A Dispenzieri
    M A Gertz
    M Q Lacy
    D Dingli
    J R Mikhael
    V Roy
    R A Kyle
    P R Greipp
    S Kumar
    S J Mandrekar
    Leukemia, 2011, 25 : 689 - 696
  • [3] Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis (vol 4, pg 689, 2011)
    Kapoor, P.
    Rajkumar, S. V.
    Dispenzieri, A.
    Gertz, M. A.
    Lacy, M. Q.
    Dingli, D.
    Mikhael, J. R.
    Roy, V.
    Kyle, R. A.
    Greipp, P. R.
    Kumar, S.
    Mandrekar, S. J.
    LEUKEMIA, 2011, 25 (09) : 1523 - 1524
  • [4] Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
    Kapoor, Prashant
    Rajkumar, S. Vincent
    Dispenzieri, Angela
    Lacy, Martha Q.
    Dingli, David
    Kyle, Robert
    Gertz, Morie A.
    Greipp, Philip R.
    Kumar, Shaji
    Mandrekar, Sumithra J.
    BLOOD, 2009, 114 (22) : 254 - 255
  • [5] Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
    Zweegman, Sonja
    van der Holt, Bronno
    Mellqvist, Ulf-Henrik
    Salomo, Morten
    Bos, Gerard M. J.
    Levin, Mark-David
    Visser-Wisselaar, Heleen
    Hansson, Markus
    van der Velden, Annette W. G.
    Deenik, Wendy
    Gruber, Astrid
    Coenen, Juleon L. L. M.
    Plesner, Torben
    Klein, Saskia K.
    Tanis, Bea C.
    Szatkowski, Damian L.
    Brouwer, Rolf E.
    Westerman, Matthijs
    Leys, M. B. L.
    Sinnige, Harm A. M.
    Haukas, Einar
    van der Hem, Klaas G.
    Durian, Marc F.
    Mattijssen, E. J. M.
    van de Donk, Niels W. C. J.
    Stevens-Kroef, Marian J. P. L.
    Sonneveld, Pieter
    Waage, Anders
    BLOOD, 2016, 127 (09) : 1109 - 1116
  • [6] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
    Mateos, Maria-Victoria
    Cavo, Michele
    Blade, Joan
    Dimopoulos, Meletios A.
    Suzuki, Kenshi
    Jakubowiak, Andrzej
    Knop, Stefan
    Doyen, Chantal
    Lucio, Paulo
    Nagy, Zsolt
    Pour, Ludek
    Cook, Mark
    Grosicki, Sebastian
    Crepaldi, Andre H.
    Liberati, Anna Marina
    Campbell, Philip
    Shelekhova, Tatiana
    Yoon, Sung-Soo
    Iosava, Genadi
    Fujisaki, Tomoaki
    Garg, Mamta
    Krevvata, Maria
    Wang, Jianping
    Kudva, Anupa
    Ukropec, Jon
    Wroblewski, Susan
    Kobos, Rachel
    San-Miguel, Jesus
    BLOOD, 2019, 134
  • [7] Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE
    Mateos, Maria-Victoria
    Dimopoulos, Meletios A.
    Cavo, Michele
    Suzuki, Kenshi
    Knop, Stefan
    Doyen, Chantal
    Lucio, Paulo
    Nagy, Zsolt
    Pour, Ludek
    Grosicki, Sebastian
    Crepaldi, Andre
    Liberati, Anna Marina
    Campbell, Philip
    Yoon, Sung-Soo
    Iosava, Genadi
    Fujisaki, Tomoaki
    Garg, Mamta
    Iida, Shinsuke
    Blade, Joan
    Ukropec, Jon
    Pei, Huiling
    Van Rampelbergh, Rian
    Kudva, Anupa
    Qi, Ming
    San-Miguel, Jesus
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 785 - 798
  • [8] Oral melphalan, prednisone,thalidomide versus oral melphalan, prednisone in elderly newly diagnosed myeloma patients
    Palumbo, A.
    Bringhen, S.
    Caravita, T.
    Falcone, A.
    Callea, V.
    Cangialosi, C.
    Grasso, M.
    Galli, M.
    Rossini, F.
    Catalano, L.
    Montanaro, M.
    De Stefano, V.
    Magarotto, V.
    Avonto, I.
    Musto, P.
    Liberati, A. M.
    Cavo, M.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 147 - 147
  • [9] Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Lee, Jae Hoon
    Moreau, Philippe
    Niesvizky, Ruben
    Dimopoulos, Meletios
    Hajek, Roman
    Pour, Ludek
    Jurczyszyn, Artur
    Qiu, Lugui
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Osman, Muhtarjan
    Paiva, Bruno
    San-Miguel, Jesus
    BLOOD, 2019, 133 (18) : 1953 - 1963
  • [10] Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
    Fu, Weijun
    Bang, Soo-Mee
    Huang, Honghui
    Kim, Kihyun
    Li, Wei
    An, Gang
    Lee, Je-Jung
    Cai, Zhen
    Jin, Jie
    Wang, Yafei
    Chim, Chor Sang
    Carson, Robin
    Liu, Rui
    Zhao, Man
    Chen, Xi
    Cui, Canchan
    Hou, Jian
    Wang, Jianxiang
    ANNALS OF HEMATOLOGY, 2025, 104 (01) : 515 - 525
12345